Bartyik Katalin, Bede Olga, Tiszlavicz Laszlo, Onozo Beata, Virag Istvan, Turi Sandor
Department of Paediatrics, Albert Szent-Györgyi Medical and Pharmaceutical Centre, Faculty of Medicine, University of Szeged, 14-15 Koranyi fasor, 6720 Szeged, Hungary.
Eur J Pediatr. 2004 Dec;163(12):731-7. doi: 10.1007/s00431-004-1527-5.
Pulmonary capillary haemangiomatosis (PCH) in childhood is a rarity, characterised by the uncontrolled proliferation of pulmonary microvessels which may invade pulmonary, bronchial and vascular structures, resulting in diffuse alveolar haemorrhage, manifesting clinically in haemoptysis, dyspnoea and symptoms of pulmonary hypertension (PH). A 14-year-old boy with some particular features (pericardial effusion and thrombocytopenia) is presented and 14 paediatric/adolescent cases from the literature are surveyed. The diagnostic problems and difficulties are discussed, including the importance of imaging (high-resolution CT) and histopathological studies, with the aim of providing a clear-cut distinction of PCH from other conditions such as primary PH (PPH). The literature data can be regarded as ambiguous: both similarities and relatively sharp distinctions between PCH and PPH are to be found. New developments in the field of genetics are also discussed. The early coexistence of PCH and other (vascular) disorders and associations, involving focal or diffuse, disseminated forms is summarised briefly. Conclusion. The diagnosis of this progressive disorder may lead to effective therapy. Treatment possibilities include the rapidly evolving field of anti-angiogenic therapy, but at present lung transplantation is universally accepted as the final definitive treatment for pulmonary capillary haemangiomatosis.
儿童期肺毛细血管瘤病(PCH)较为罕见,其特征是肺微血管不受控制地增殖,可侵犯肺、支气管和血管结构,导致弥漫性肺泡出血,临床上表现为咯血、呼吸困难和肺动脉高压(PH)症状。本文介绍了一名具有一些特殊特征(心包积液和血小板减少症)的14岁男孩,并对文献中的14例儿科/青少年病例进行了调查。讨论了诊断问题和困难,包括影像学(高分辨率CT)和组织病理学研究的重要性,目的是明确区分PCH与其他疾病,如原发性肺动脉高压(PPH)。文献数据存在模糊性:PCH与PPH之间既有相似之处,也有较为明显的区别。还讨论了遗传学领域的新进展。简要总结了PCH与其他(血管)疾病及关联(包括局灶性或弥漫性、播散性形式)的早期共存情况。结论。这种进行性疾病的诊断可能会带来有效的治疗。治疗选择包括迅速发展的抗血管生成治疗领域,但目前肺移植被普遍认为是肺毛细血管瘤病的最终确定性治疗方法。